Multiple myeloma screening

	Multiple myeloma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple Myeloma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Multiple myeloma screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple myeloma screening All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple myeloma screening
CDC on Multiple myeloma screening
Multiple myeloma screening in the news
Blogs on Multiple myeloma screening
Directions to Hospitals Treating Multiple myeloma
Risk calculators and risk factors for Multiple myeloma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

There is insufficient evidence to recommend routine screening for multiple myeloma.^[1]^[2]

Screening

Monoclonal gammopathy of undetermined significance

Monoclonal gammopathy of undetermined significance, or (MGUS), carries a 1% per year risk of progression to active multiple myeloma. Given the risk of progression, patients should be screened via monitoring of complete blood count and serum protein electrophoresis (SPEP) typically once yearly. The frequency of screening may vary depending on the MGUS risk group. High-risk patients may need more frequent monitoring.

Smoldering multiple myeloma

Smoldering multiple myeloma carries a 10% per year risk of progression to active multiple myeloma. Given the risk of progression, patients should be screened via monitoring of complete blood count and serum protein electrophoresis (SPEP) typically once yearly. The frequency of screening may vary depending on the smoldering multiple myeloma risk group. High-risk smoldering multiple myeloma patients may need more frequent monitoring.